MST1R and neoplasm: 10G1 was chosen as the lead candidate for its ability to specifically bind to and immunoprecipitate RON expressed on the surface of cancer cells, potently block MSP stimulated downstream signaling of RON receptor, and its ability to elicit strong antibody dependent cellular cytotoxicity (ADCC) responses which can aid in tumour cell elimination.